The role of visfatin in cancer proliferation, angiogenesis, metastasis, drug resistance and clinical prognosis

References

• Samal B, Sun Y, Stearns G, Xie C, Suggs S, McNiece I. Cloning and characterization of the cDNA encoding a novel human pre-B-cell colony-enhancing factor. Mol Cell Biol. 1994;14(2):1431–1437.8289818
   PubMed Web of Science ®Google Scholar
• Gerner RR, Klepsch V, Macheiner S, et al. NAD metabolism fuels human and mouse intestinal inflammation. Gut. 2018;67(10):1813–1823. doi:10.1136/gutjnl-2017-31424128877980
   PubMed Web of Science ®Google Scholar
• Revollo JR, Grimm AA, Imai S. The NAD biosynthesis pathway mediated by nicotinamide phosphoribosyltransferase regulates Sir2 activity in mammalian cells. J Biol Chem. 2004;279(49):50754–50763. doi:10.1074/jbc.M40838820015381699
   PubMed Web of Science ®Google Scholar
• Hong SM, Hwang SW, Wang T, et al. Increased NAD(H) pool promotes colon cancer progression by suppressing ROS level. Cancer Sci. 2018;110(2):629-638. doi: 10.1111/cas.13886
   Google Scholar
• Mohammadi M, Mianabadi F, Mehrad-Majd H. Circulating visfatin levels and cancers risk: a systematic review and meta-analysis. J Cell Physiol. 2018;234:5011–5022.30471099
   PubMed Web of Science ®Google Scholar
• Wang XY, Wang JZ, Gao L, et al. Inhibition of nicotinamide phosphoribosyltransferase and depletion of nicotinamide adenine dinucleotide contribute to arsenic trioxide suppression of oral squamous cell carcinoma. Toxicol Appl Pharmacol. 2017;331:54–61. doi:10.1016/j.taap.2017.05.00828501332
   PubMed Web of Science ®Google Scholar
• Ju HQ, Zhuang ZN, Li H, et al. Regulation of the Nampt-mediated NAD salvage pathway and its therapeutic implications in pancreatic cancer. Cancer Lett. 2016;379(1):1–11. doi:10.1016/j.canlet.2016.05.02427233476
   PubMed Web of Science ®Google Scholar
• Sharif T, Ahn DG, Liu RZ, et al. The NAD(+) salvage pathway modulates cancer cell viability via p73. Cell Death Differ. 2016;23(4):669–680. doi:10.1038/cdd.2015.13426586573
   PubMed Web of Science ®Google Scholar
• Zhang HP, Zou J, Xu ZQ, et al. Association of leptin, visfatin, apelin, resistin and adiponectin with clear cell renal cell carcinoma. Oncol Lett. 2017;13(1):463–468. doi:10.3892/ol.2016.540828123583
   PubMed Web of Science ®Google Scholar
• Sawicka-Gutaj N, Waligorska-Stachura J, Andrusiewicz M, et al. Nicotinamide phosphorybosiltransferase overexpression in thyroid malignancies and its correlation with tumor stage and with survivin/survivin DEx3 expression. Tumour Biol. 2015;36(10):7859–7863. doi:10.1007/s13277-015-3506-z25946974
   PubMedGoogle Scholar
• Venkateshaiah SU, Khan S, Ling W, et al. NAMPT/PBEF1 enzymatic activity is indispensable for myeloma cell growth and osteoclast activity. Exp Hematol. 2013;41(6):547–557 e542. doi:10.1016/j.exphem.2013.02.00823435312
   PubMed Web of Science ®Google Scholar
• Zhu J, Sanborn JZ, Benz S, et al. The UCSC cancer genomics browser. Nat Methods. 2009;6(4):239–240. doi:10.1038/nmeth0409-23919333237
   PubMed Web of Science ®Google Scholar
• Zhao H, Tang W, Chen X, et al. The NAMPT/E2F2/SIRT1 axis promotes proliferation and inhibits p53-dependent apoptosis in human melanoma cells. Biochem Biophys Res Commun. 2017;493(1):77–84. doi:10.1016/j.bbrc.2017.09.07128919418
   PubMed Web of Science ®Google Scholar
• Sun Y, Zhu S, Wu Z, et al. Elevated serum visfatin levels are associated with poor prognosis of hepatocellular carcinoma. Oncotarget. 2017;8(14):23427–23435. doi:10.18632/oncotarget.1508028178643
   PubMedGoogle Scholar
• Yang J, Zhang K, Song H, et al. Visfatin is involved in promotion of colorectal carcinoma malignancy through an inducing EMT mechanism. Oncotarget. 2016;7(22):32306–32317. doi:10.18632/oncotarget.861527058759
   PubMedGoogle Scholar
• Hung AC, Lo S, Hou MF, et al. Extracellular visfatin-promoted malignant behavior in breast cancer is mediated through c-Abl and STAT3 activation. Clin Cancer Res. 2016;22(17):4478–4490. doi:10.1158/1078-0432.CCR-15-270427036136
   PubMed Web of Science ®Google Scholar
• Ke HL, Lin HH, Li WM, et al. High visfatin expression predicts poor prognosis of upper tract urothelial carcinoma patients. Am J Cancer Res. 2015;5(8):2447–2454.26396920
   PubMed Web of Science ®Google Scholar
• Lu GW, Wang QJ, Xia MM, Qian J. Elevated plasma visfatin levels correlate with poor prognosis of gastric cancer patients. Peptides. 2014;58:60–64. doi:10.1016/j.peptides.2014.05.01624911837
   PubMed Web of Science ®Google Scholar
• Zhao W, Chen R, Zhao M, Li L, Fan L, Che XM. High glucose promotes gastric cancer chemoresistance in vivo and in vitro. Mol Med Rep. 2015;12(1):843–850. doi:10.3892/mmr.2015.352225815791
   PubMed Web of Science ®Google Scholar
• Li XY, Tang SH, Zhou XC, Ye YH, Xu XQ, Li RZ. Preoperative serum visfatin levels and prognosis of breast cancer among Chinese women. Peptides. 2014;51:86–90. doi:10.1016/j.peptides.2013.11.01024269296
   PubMed Web of Science ®Google Scholar
• Zhou SJ, Bi TQ, Qin CX, Yang XQ, Pang K. Expression of NAMPT is associated with breast invasive ductal carcinoma development and prognosis. Oncol Lett. 2018;15(5):6648–6654. doi:10.3892/ol.2018.816429725408
   PubMed Web of Science ®Google Scholar
• Cagnetta A, Cea M, Calimeri T, et al. Intracellular NAD(+) depletion enhances bortezomib-induced anti-myeloma activity. Blood. 2013;122(7):1243–1255. doi:10.1182/blood-2013-02-48351123823317
   PubMed Web of Science ®Google Scholar
• Aguirre-Gamboa R, Gomez-Rueda H, Martinez-Ledesma E, et al. SurvExpress: an online biomarker validation tool and database for cancer gene expression data using survival analysis. PLoS One. 2013;8(9):e74250. doi:10.1371/journal.pone.007425024066126
   PubMed Web of Science ®Google Scholar
• Gyorffy B, Schafer R. Meta-analysis of gene expression profiles related to relapse-free survival in 1,079 breast cancer patients. Breast Cancer Res Treat. 2009;118(3):433–441. doi:10.1007/s10549-008-0242-819052860
   PubMed Web of Science ®Google Scholar
• Buldak RJ, Buldak L, Polaniak R, et al. Visfatin affects redox adaptative responses and proliferation in Me45 human malignant melanoma cells: an in vitro study. Oncol Rep. 2013;29(2):771–778. doi:10.3892/or.2012.217523232726
   PubMed Web of Science ®Google Scholar
• Ninomiya S, Shimizu M, Imai K, et al. Possible role of visfatin in hepatoma progression and the effects of branched-chain amino acids on visfatin-induced proliferation in human hepatoma cells. Cancer Prev Res (Phila). 2011;4(12):2092–2100. doi:10.1158/1940-6207.CAPR-11-034021952585
   PubMed Web of Science ®Google Scholar
• Park HJ, Kim SR, Kim SS, et al. Visfatin promotes cell and tumor growth by upregulating Notch1 in breast cancer. Oncotarget. 2014;5(13):5087–5099. doi:10.18632/oncotarget.208624970818
   PubMed Web of Science ®Google Scholar
• Gholinejad Z, Kheiripour N, Nourbakhsh M, et al. Extracellular NAMPT/Visfatin induces proliferation through ERK1/2 and AKT and inhibits apoptosis in breast cancer cells. Peptides. 2017;92:9–15. doi:10.1016/j.peptides.2017.04.00728442350
   PubMed Web of Science ®Google Scholar
• Behrouzfar K, Alaee M, Nourbakhsh M, Gholinejad Z, Golestani A. Extracellular NAMPT/visfatin causes p53 deacetylation via NAD production and SIRT1 activation in breast cancer cells. Cell Biochem Funct. 2017;35(6):327–333. doi:10.1002/cbf.327928845527
   PubMed Web of Science ®Google Scholar
• Wang Y, Gao C, Zhang Y, et al. Visfatin stimulates endometrial cancer cell proliferation via activation of PI3K/Akt and MAPK/ERK1/2 signalling pathways. Gynecol Oncol. 2016;143(1):168–178. doi:10.1016/j.ygyno.2016.07.10927473926
   PubMed Web of Science ®Google Scholar
• Abu Aboud O, Chen CH, Senapedis W, Baloglu E, Argueta C, Weiss RH. Dual and specific inhibition of NAMPT and PAK4 by KPT-9274 decreases kidney cancer growth. Mol Cancer Ther. 2016;15(9):2119–2129. doi:10.1158/1535-7163.MCT-16-019727390344
   PubMed Web of Science ®Google Scholar
• Bong IP, Ng CC, Fakiruddin SK, Lim MN, Zakaria Z. Small interfering RNA-mediated silencing of nicotinamide phosphoribosyltransferase (NAMPT) and lysosomal trafficking regulator (LYST) induce growth inhibition and apoptosis in human multiple myeloma cells: a preliminary study. Bosn J Basic Med Sci. 2016;16(4):268–275. doi:10.17305/bjbms.2016.156827754828
   PubMed Web of Science ®Google Scholar
• Kim JG, Kim EO, Jeong BR, et al. Visfatin stimulates proliferation of MCF-7 human breast cancer cells. Mol Cells. 2010;30(4):341–345. doi:10.1007/s10059-010-0124-x20848232
   PubMed Web of Science ®Google Scholar
• Kim SR, Jung YH, Park HJ, et al. Upregulation of thromboxane synthase mediates visfatin-induced interleukin-8 expression and angiogenic activity in endothelial cells. Biochem Biophys Res Commun. 2012;418(4):662–668. doi:10.1016/j.bbrc.2012.01.07222293189
   PubMed Web of Science ®Google Scholar
• Park JW, Kim WH, Shin SH, et al. Visfatin exerts angiogenic effects on human umbilical vein endothelial cells through the mTOR signaling pathway. Biochim Biophys Acta. 2011;1813(5):763–771. doi:10.1016/j.bbamcr.2011.02.00921329734
   PubMed Web of Science ®Google Scholar
• Bae YH, Park HJ, Kim SR, et al. Notch1 mediates visfatin-induced FGF-2 up-regulation and endothelial angiogenesis. Cardiovasc Res. 2011;89(2):436–445. doi:10.1093/cvr/cvq27620817637
   PubMed Web of Science ®Google Scholar
• Kim JY, Bae YH, Bae MK, et al. Visfatin through STAT3 activation enhances IL-6 expression that promotes endothelial angiogenesis. Biochim Biophys Acta. 2009;1793(11):1759–1767. doi:10.1016/j.bbamcr.2009.09.00619751774
   PubMed Web of Science ®Google Scholar
• Xiao J, Xiao ZJ, Liu ZG, et al. Involvement of dimethylarginine dimethylaminohydrolase-2 in visfatin-enhanced angiogenic function of endothelial cells. Diabetes Metab Res Rev. 2009;25(3):242–249. doi:10.1002/dmrr.93919229883
   PubMed Web of Science ®Google Scholar
• Adya R, Tan BK, Chen J, Randeva HS. Pre-B cell colony enhancing factor (PBEF)/visfatin induces secretion of MCP-1 in human endothelial cells: role in visfatin-induced angiogenesis. Atherosclerosis. 2009;205(1):113–119. doi:10.1016/j.atherosclerosis.2008.11.02419166999
   PubMed Web of Science ®Google Scholar
• Adya R, Tan BK, Punn A, Chen J, Randeva HS. Visfatin induces human endothelial VEGF and MMP-2/9 production via MAPK and PI3K/Akt signalling pathways: novel insights into visfatin-induced angiogenesis. Cardiovasc Res. 2008;78(2):356–365. doi:10.1093/cvr/cvm11118093986
   PubMed Web of Science ®Google Scholar
• Kim SR, Bae SK, Choi KS, et al. Visfatin promotes angiogenesis by activation of extracellular signal-regulated kinase 1/2. Biochem Biophys Res Commun. 2007;357(1):150–156. doi:10.1016/j.bbrc.2007.03.10517408594
   PubMed Web of Science ®Google Scholar
• Kato H, Ito E, Shi W, et al. Efficacy of combining GMX1777 with radiation therapy for human head and neck carcinoma. Clin Cancer Res. 2010;16(3):898–911. doi:10.1158/1078-0432.CCR-09-194520103674
   PubMed Web of Science ®Google Scholar
• Ilhan TT, Kebapcilar A, Yilmaz SA, et al. Relations of serum visfatin and resistin levels with endometrial cancer and factors associated with its prognosis. Asian Pac J Cancer Prev. 2015;16(11):4503–4508.26107194
   PubMedGoogle Scholar
• Liu T, Miao Z, Jiang J, et al. Visfatin mediates SCLC cells migration across brain endothelial cells through upregulation of CCL2. Int J Mol Sci. 2015;16(5):11439–11451. doi:10.3390/ijms16051143925993304
   PubMed Web of Science ®Google Scholar
• Wang G, Tian W, Liu Y, et al. Visfatin triggers the cell motility of non-small cell lung cancer via up-regulation of matrix metalloproteinases. Basic Clin Pharmacol Toxicol. 2016;119(6):548–554. doi:10.1111/bcpt.1262327224551
   PubMed Web of Science ®Google Scholar
• Wang GJ, Shen NJ, Cheng L, Yehan F, Huang H, Li KH. Visfatin triggers the in vitro migration of osteosarcoma cells via activation of NF-kappaB/IL-6 signals. Eur J Pharmacol. 2016;791:322–330. doi:10.1016/j.ejphar.2016.08.02927568842
   PubMed Web of Science ®Google Scholar
• Li Y, Li X, Liu KR, Zhang JN, Liu Y, Zhu Y. Visfatin derived from ascites promotes ovarian cancer cell migration through Rho/ROCK signaling-mediated actin polymerization. Eur J Cancer Prev. 2015;24(3):231–239. doi:10.1097/CEJ.000000000000006425055182
   PubMed Web of Science ®Google Scholar
• Santidrian AF, LeBoeuf SE, Wold ED, Ritland M, Forsyth JS, Felding BH. Nicotinamide phosphoribosyltransferase can affect metastatic activity and cell adhesive functions by regulating integrins in breast cancer. DNA Repair (Amst). 2014;23:79–87. doi:10.1016/j.dnarep.2014.08.00625263164
   PubMed Web of Science ®Google Scholar
• Slomian G, Swietochowska E, Nowak G, Pawlas K, Zelazko A, Nowak P. Chemotherapy and plasma adipokines level in patients with colorectal cancer. Postepy Hig Med Dosw (Online). 2017;71:281–290.28402255
   PubMedGoogle Scholar
• Cao Z, Liang N, Yang H, Li S. Visfatin mediates doxorubicin resistance in human non-small-cell lung cancer via Akt-mediated up-regulation of ABCC1. Cell Prolif. 2017;50(5). doi:10.1111/cpr.12368
   Web of Science ®Google Scholar
• Yan X, Zhao J, Zhang R. Visfatin mediates doxorubicin resistance in human colorectal cancer cells via up regulation of multidrug resistance 1 (MDR1). Cancer Chemother Pharmacol. 2017;80(2):395–403. doi:10.1007/s00280-017-3365-y28667355
   PubMed Web of Science ®Google Scholar
• Elf AK, Bernhardt P, Hofving T, et al. NAMPT inhibitor GMX1778 enhances the efficacy of 177Lu-DOTATATE treatment of neuroendocrine tumors. J Nucl Med. 2017;58(2):288–292. doi:10.2967/jnumed.116.17758427688470
   PubMed Web of Science ®Google Scholar
• Feng J, Yan PF, Zhao HY, Zhang FC, Zhao WH, Feng M. Inhibitor of nicotinamide phosphoribosyltransferase sensitizes glioblastoma cells to temozolomide via activating ROS/JNK signaling pathway. Biomed Res Int. 2016;2016:1450843. doi:10.1155/2016/145084328097126
   PubMed Web of Science ®Google Scholar
• Xie H, Tang SY, Luo XH, et al. Insulin-like effects of visfatin on human osteoblasts. Calcif Tissue Int. 2007;80(3):201–210. doi:10.1007/s00223-006-0155-717340225
   PubMed Web of Science ®Google Scholar
• Fukuhara A, Matsuda M, Nishizawa M, et al. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science. 2005;307(5708):426–430. doi:10.1126/science.109724315604363
   PubMed Web of Science ®Google Scholar